TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Inclusion Criteria:

• Has a diagnosis of HCC confirmed by radiology, histology, or cytology -≥18 years
• China liver cancer staging: Ib-IIIa
• Child-Pugh score ≤6 point
• Previous TACE treatment(≤2 times) is permitted
• Adequate organ and marrow function

Exclusion Criteria:

• Participants who had another previous or current malignant tumor, except forearly-stage cancer with low risk of recurrence or a malignant tumor curatively treated >5 years prior to enrolment with no recurrence
• Participants who have severe allergy to iodine, and unable to receive TACE
• Participants who have undergone a liver transplant or allogeneic bone marrowtransplantation, or those who are in the waiting list for liver or bone marrowtransplantation
• Participants who had congenital or acquired immune deficiency, such as HIV infection
• Participants who had a history of gastrointestinal bleeding within 6 months prior torandomization or a definite tendency of gastrointestinal bleeding
• Participants who had undergone arterial thromboembolism within 6 months prior torandomization or a definite tendency of gastrointestinal bleeding, such ascerebrovascular accident, ≥ CTCAE grade 3 deep vein thrombosis and pulmonary embolism